Business Wire

Duco Launches the First Agentic Operations Platform for Financial Services

27.5.2026 09:20:00 CEST | Business Wire | Press Release

Share

Duco, today launched the first agentic Operations platform for financial services. Built on the engine that already processes 20 billion transactions every month for more than 200 clients, including seven of the top 20 banks and ten of the top 20 asset managers, the platform brings together everything firms need to run post-trade Operations alongside autonomous agents, safely and at scale.

The launch establishes a breakthrough the industry has been waiting for.

A tool surface, purpose-built for agents. Duco has unbundled its platform into a new alternative agent layer that reconfigures its platform into hundreds of discrete capabilities servicing post trade. Model Context Protocol (MCP) gives capabilities covering reconciliation, data preparation, data access, audit trails, exception management, document creation and more. For the first time, agents have a verified, deterministic toolset built specifically for post-trade. Agents do not replace matching, rules or audit; they use them. Provable accuracy is the reason agents can be trusted in Operations.

Duco also announces the pacesetters cohort. Duco has convened a group of the most ambitious post-trade Operations leaders in financial services. Pacesetters have first access to capabilities as they ship, direct input into product development, and a head-start on the operational model of the future. 10 firms are already live with Duco agents in production today. Our next wave of Pacesetters opens today.

Why post-trade, and why now

Post-trade Operations sit at the intersection of three pressures that agentic AI is uniquely positioned to address: shrinking settlement windows, growing transaction volumes, and a generational shift in who does the work and how. Manual handling is increasingly hard to justify. Legacy systems are a dead-end for AI. The firms that move first will set the standard for everyone who follows.

"For more than a decade, our clients have trusted Duco to reconcile the most complex data in capital markets. They are now telling us that agents will run a meaningful share of post-trade Operations within three years. Duco is assembling the most powerful set of tools and context ever built for Operations to enable this," said Christian Nentwich, CEO and co-founder of Duco.

"What we are launching today is not another AI feature," Nentwich continued. "It is the operating system for post-trade in the agentic era. The Pacesetters are defining what good looks like for everyone else and we will share what they learn so the whole industry can move faster."

Pacesetters are already reporting results that would have been impossible six months ago. In early deployments, building a new reconciliation process on the Duco Platform has dropped from two days to four hours with roughly twenty minutes of agent runtime and the rest spent on human review. Auto-built workflows from raw inputs, continuous optimisation of existing processes, and accelerated exception investigation are moving from roadmap to daily operating reality.

Availability and how to engage

The Duco agentic Operations platform is available today. Applications for the next Pacesetters wave are open to qualifying financial services firms visit du.co or contact your Duco representative. A demonstration of Agentic Workspace and the tool surface is available at du.co/agentic-workspace.

About Duco

Duco is empowering financial services to transform the work undertaken in Operations by automating manual work and elevating humans from task workers to decision makers.

We do this with a combination of proprietary technique, innovative cloud computing, artificial intelligence technology, and deep subject matter expertise.

Our agentic Operations platform gives firms the ability to unlock full end-to-end reconciliation, data trust and automation of their data, regardless of source, format or structure.

By partnering with the industry's leading firms, we are helping to rethink operating models, increase efficiency, strengthen governance and regulatory compliance, reduce risk, streamline processes and build the workforce of the future.

More than 10,000 users across 30+ countries process billions of data records every week using the platform.

Duco is headquartered in London, with offices in New York, Wroclaw, Antwerp and Singapore. Customers include global banks, investment managers, exchanges and insurance firms, such as CIBC Mellon, ING and Man Group. For more information go to www.du.co

View source version on businesswire.com: https://www.businesswire.com/news/home/20260527267379/en/

Contacts

Duco@cognitomedia.com
07983268447

(c) 2024 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Azafaros to Present at BIO International Convention 202615.6.2026 07:00:00 CEST | Press Release

Azafaros, a private company building a portfolio to become a leader in lysosomal storage disorders (LSDs), focused on addressing neurological symptoms, today announced that it will present at the 2026 BIO International Convention taking place in San Diego, USA, from June 22-25. The company’s presentation is scheduled for Monday, June 22 at 4:30 PM in Theater 4. The presentation will highlight Azafaros’ progress in developing nizubaglustat, its lead investigational compound for the treatment of rare lysosomal storage disorders with neurological involvement, including GM1 and GM2 gangliosidoses (GM1/GM2) and Niemann-Pick type C disease (NPC). Nizubaglustat is currently in two Phase 3 registrational studies (NAVIGATE) treating patients with GM1/GM2 and NPC and expects to report topline data from the studies in 2028. “BIO provides an important opportunity to update our progress as we continue advancing nizubaglustat through late-stage clinical development,” said Stefano Portolano, CEO at A

Teledyne FLIR Defense Launches Black Recon™ Autonomous Micro-Drone15.6.2026 06:05:00 CEST | Press Release

Teledyne FLIR Defense, part of Teledyne Technologies Incorporated (NYSE: TDY), today announced at Eurosatory the market launch of Black Recon™, an autonomously launched micro-drone system that delivers continuous, untethered reconnaissance from military vehicles and fixed installations. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260614388428/en/ Teledyne FLIR Defense announced at Eurosatory the market launch of Black Recon™, an autonomously launched micro-drone that delivers continuous, untethered reconnaissance from military vehicles and fixed installations. Black Recon allows crews to launch, operate, recover, and recharge up to three UAS without leaving their platform, reducing operator risk. Designed for vehicle integration, Black Recon allows crews to launch, operate, recover, and recharge up to three unmanned aerial systems without leaving their platform, reducing risk and accelerating decision-making. “Black Recon

OM Pharma to Unveil the Largest Multi-Country Real-World Evidence Study on Broncho‑Vaxom® (OM‑85) for RTI Prevention at EAACI 202614.6.2026 10:00:00 CEST | Press Release

OM Pharma will reveal preliminary results from the REACH study at the European Academy of Allergy and Clinical Immunology (EAACI) Congress. REACH is the first and largest multi-country real-world evidence (RWE) study to date evaluating the impact of Broncho-Vaxom® in patients with recurrent respiratory tract infections (RTIs).1,2 The findings offer critical new clinical evidence of the therapy's effectiveness in everyday clinical practice. In a real-world cohort of 15,794 paediatric (aged >1 year), adolescent, adult and elderly patients in China, Italy, and Belgium, Broncho-Vaxom® was associated with reductions in RTI recurrence and healthcare utilisation at 12 and 24 months after treatment initiation, compared with the 12 months prior to starting the therapy.1 “The REACH real-world evidence study shows that Broncho-Vaxom® can significantly reduce infections requiring medical visits across age groups and co-morbidities,” said Anna Thomas, Chief Scientific Officer at OM Pharma. “Recurre

Incyte Announces New Positive Data at EHA 2026 Showed INCA033989 Achieved Rapid, Robust and Sustained Clinical and Molecular Responses and Was Well Tolerated in Patients with Myelofibrosis and Essential Thrombocythemia13.6.2026 17:15:00 CEST | Press Release

Incyte (Nasdaq:INCY) today announced updated clinical data from two Phase 1 studies evaluating the safety, tolerability and efficacy of INCA033989, a first-in-class mutant calreticulin (mutCALR)-targeted monoclonal antibody, in patients with mutCALR-expressing myeloproliferative neoplasms (MPNs). INCA033989 demonstrated rapid, clinically meaningful responses and consistent molecular activity across both myelofibrosis (MF) and essential thrombocythemia (ET), with convergent evidence supporting the potential for disease modification. These findings are being presented in oral and poster presentations at the European Hematology Association (EHA) 2026 Congress in Stockholm, Sweden (Session: Myeloproliferative neoplasms – Clinical, Presentation numbers: S216, PS1983, PF884). “The data presented at EHA 2026 demonstrate clinically meaningful and consistent responses with INCA033989 across both myelofibrosis and essential thrombocythemia,” said Pablo J. Cagnoni, M.D., President of Incyte and G

Results from Incyte’s Pivotal Phase 3 frontMIND Trial of Tafasitamab (Monjuvi ® /Minjuvi ® ) Combination Presented at the 2026 European Hematology Association (EHA) Congress Plenary Showed Prolonged Progression Free Survival13.6.2026 12:00:00 CEST | Press Release

Incyte (Nasdaq:INCY) today announced positive results from the pivotal Phase 3 frontMIND trial evaluating the efficacy and safety of tafasitamab (Monjuvi®/Minjuvi®), a humanized Fc-modified cytolytic CD19-targeting monoclonal antibody, and lenalidomide added to R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone; Tafa-Len-R-CHOP) versus R-CHOP, the current standard of care, as a first-line treatment for adults with previously untreated diffuse large B-cell lymphoma (DLBCL) or high-grade B-cell lymphoma (HGBL). Eligible patients had an International Prognostic Index (IPI) score of 3-5, or, for patients ≤60 years of age, an age-adjusted IPI (aaIPI) of 2-3. These data are being highlighted in a prestigious Plenary Abstracts Session at the European Hematology Association (EHA) 2026 Congress, being held June 11 - 14, 2026, in Stockholm, Sweden (Abstract # S101. Plenary Abstract Session. June 13, 6:00 - 7:30 a.m. ET [12:00-1:30 p.m. CEST]). frontMIND results were als

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye